Literature DB >> 31406974

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.

M E Pavel, E Baudin, K E Öberg, J D Hainsworth, M Voi, N Rouyrre, M Peeters, D J Gross, J C Yao.   

Abstract

Entities:  

Year:  2019        PMID： 31406974      PMCID： PMC8902958          DOI： 10.1093/annonc/mdz222

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  1 in total

1.  Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment.

Authors:  Angela Lamarca; Mauro Cives; Louis de Mestier; Joakim Crona; Francesca Spada; Kjell Öberg; Marianne Pavel; Teresa Alonso-Gordoa
Journal:  World J Gastroenterol       Date:  2021-03-14       Impact factor: 5.742
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.